Trials / Recruiting
RecruitingNCT05160584
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | There is no interventional treatment component for participants with RRMM in this study. |
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2028-04-30
- Completion
- 2028-07-31
- First posted
- 2021-12-16
- Last updated
- 2026-04-13
Locations
87 sites across 11 countries: Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT05160584. Inclusion in this directory is not an endorsement.